Country: Unjoni Ewropea
Lingwa: Ingliż
Sors: EMA (European Medicines Agency)
Clostridium-perfringens-type-A alpha toxoid
Intervet International BV
QI01AB08
adjuvanted vaccine against necrotic enteritis of chickens due to Clostridium perfringens
Chicken
Immunologicals for aves
For the active immunisation of chickens to provide passive immunisation against necrotic enteritis to their progeny, during the laying period.To reduce mortality and the incidence and severity of lesions caused by Clostridium-perfringens-type-A-induced necrotic enteritis. Efficacy was demonstrated by challenge of chicks approximately three weeks after hatching.The onset of passive transfer of immunity: 6 weeks following completion of the vaccination procedure.The duration of passive transfer of immunity: 51 weeks following completion of the vaccination procedure.
Revision: 2
Withdrawn
2009-04-16
Medicinal product no longer authorised 17 B. PACKAGE LEAFLET Medicinal product no longer authorised 18 PACKAGE LEAFLET FOR Netvax emulsion for injection for chickens 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Marketing authorisation holder : Intervet International B.V. Wim de Körverstraat 35 5831AN Boxmeer The Netherlands Manufacturer for the batch release: S-P Veterinary Ltd Breakspear Road South Harefield Uxbridge Middlesex, UB9 6LS United Kingdom 2. NAME OF THE VETERINARY MEDICINAL PRODUCT Netvax emulsion for injection for chickens 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) One dose (0.5ml) contains: Active substance: _Clostridium perfringens_ Type A alpha toxoid Not less than 6.8 IU * Adjuvant Light Mineral Oil 0.31 ml Excipients Thiomersal 0.035-0.05 mg * International units per ml of rabbit serum determined by haemolysis inhibition assay 4. INDICATION(S) For the active immunization of chickens to provide passive immunisation against necrotic enteritis to their progeny, during the laying period. To reduce mortality and the incidence and severity of lesions caused by _Clostridium perfringens_ Type A induced necrotic enteritis. Efficacy was demonstrated by challenge of chicks approximately three weeks after hatching. Medicinal product no longer authorised 19 The onset of passive transfer of immunity: 6 weeks following completion of the vaccination procedure The duration of passive transfer of immunity: 51 weeks following completion of the vaccination procedure 5. CONTRAINDICATIONS None 6. ADVERSE REACTIONS No systemic reactions to vaccination were seen following intramuscular vaccination. Vaccination may result in moderate swelling of the breast tissue which will resolve within 30 days. Following the second vaccination swelling may persist for at least 35 days. Swelling was very common. After administration of a double dose, local reactions may increase slightly. If you notice any seri Aqra d-dokument sħiħ
Medicinal product no longer authorised 1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Netvax emulsion for injection for chickens 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose (0.5ml) contains: Active substance: _Clostridium perfringens_ Type A alpha toxoid Not less than 6.8 IU * Adjuvant Light Mineral Oil 0.31 ml Excipients Thiomersal 0.035-0.05 mg * International units per ml of rabbit serum determined by haemolysis inhibition assay For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Emulsion for injection Off white oily emulsion. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Chickens 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the active immunization of chickens to provide passive immunisation against necrotic enteritis to their progeny, during the laying period. To reduce mortality and the incidence and severity of lesions caused by _Clostridium perfringens_ Type A induced necrotic enteritis. Efficacy was demonstrated by challenge of chicks approximately three weeks after hatching. The onset of passive transfer of immunity: 6 weeks following completion of the vaccination procedure The duration of passive transfer of immunity: 51 weeks following completion of the vaccination procedure 4.3 CONTRAINDICATIONS None Medicinal product no longer authorised 3 4.4 SPECIAL WARNINGS None. 4.5 SPECIAL PRECAUTIONS FOR USE None SPECIAL PRECAUTIONS FOR USE IN ANIMALS None SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS To the user: This product contains mineral oil. Accidental injection/self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given. If you are accidentally injected with this product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with yo Aqra d-dokument sħiħ